KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer. PMID 36701146 · JAMA Oncol · 2023-Mar-01 The record is a secondary, biomarker-focused analysis derived from a phase III randomized trial (CALGB/SWOG 80702). It does not present the primary or key secondary efficacy results of the drug intervention (celecoxib) from the parent trial. Therefore, it is excluded as not being an original formal-result report of the definitive trial's efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Resistance Training Volume on Physical and Perceptual Outcomes of Breast Cancer Survivors Submitted to a Combined Training Program: A Randomized, Single-Blinded Study. PMID 36689989 · J Phys Act Health · 2023-Mar-01 The study is a randomized trial in breast cancer survivors, but the intervention is exercise (resistance training), not a drug. The primary outcomes are functional and quality-of-life measures (e.g., strength, fatigue, time to exhaustion), not time-to-event efficacy endpoints such as OS, PFS, DFS, etc. Therefore, it does not meet the inclusion criteria for a drug-containing oncology trial with a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Network Analysis and Nomogram in the Novel Classification and Prognosis Prediction of Advanced Schistosomiasis Japonica. PMID 36689944 · Am J Trop Med Hyg · 2023-Mar-01 Study is on advanced schistosomiasis japonica, a parasitic disease, not a human malignant neoplasm. No drug-containing intervention is described.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial. PMID 36633877 · JAMA Oncol · 2023-Mar-01 Eligibility requires both a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. This study lacks both.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term Effect of Machine Learning-Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer: A Randomized Clinical Trial. PMID 36633868 · JAMA Oncol · 2023-Mar-01 The study is a randomized trial in oncology patients but does not meet all required criteria. It lacks a specified Phase III/IIIb or Phase II/III design, does not involve a drug intervention (it uses behavioral nudges), and its primary and secondary outcomes are not time-to-event efficacy endpoints (e.g., OS, PFS) but rather process measures and categorical outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells. PMID 36534496 · Clin Cancer Res · 2023-Mar-01 The record describes a secondary biomarker analysis from a phase III trial, not the original formal result report of the randomized trial's drug intervention efficacy.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. PMID 36521103 · J Clin Oncol · 2023-Mar-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. PMID 36521078 · J Clin Oncol · 2023-Mar-01 The record is from a long-term follow-up of two definitive Phase III randomized trials (TEXT and SOFT) in premenopausal breast cancer. It reports drug interventions (exemestane + OFS vs tamoxifen + OFS) with primary/key secondary time-to-event efficacy endpoints (DFS, DRFI, OS) including hazard ratios and p-values. It is an original formal result report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 4 Panel · risk visible
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. PMID 36493334 · J Clin Oncol · 2023-Mar-01 The record is a long-term follow-up report from a phase III randomized controlled trial (SOFT) evaluating adjuvant endocrine therapy in human breast cancer, with drug intervention and primary/key secondary time-to-event endpoints (DFS, OS). All required criteria are explicitly established.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD). PMID 36409969 · J Clin Oncol · 2023-Mar-01 While the study is an oncology Phase III RCT with a drug intervention and reports primary results, its primary efficacy endpoint is a symptom distress score at a fixed time point, not a time-to-event outcome like OS, PFS, or DFS. Therefore, it does not meet the required time-to-event efficacy endpoint criterion for inclusion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). PMID 36260828 · J Clin Oncol · 2023-Mar-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Online Symptom Monitoring During Pelvic Radiation Therapy: Randomized Pilot Trial of the eRAPID Intervention. PMID 36241128 · Int J Radiat Oncol Biol Phys · 2023-Mar-01 This is a randomized pilot trial in oncology patients, but it is not a Phase III/IIIb or Phase II/III trial. The intervention is a symptom monitoring system (eRAPID), not a drug intervention. The primary and secondary outcomes are feasibility, acceptability, and quality-of-life measures, not time-to-event efficacy endpoints like OS, PFS, or DFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cardiac Rehabilitation Improves Fitness in Patients With Subclinical Markers of Cardiotoxicity While Receiving Chemotherapy: A RANDOMIZED CONTROLLED STUDY. PMID 35940850 · J Cardiopulm Rehabil Prev · 2023-Mar-01 The study is an oncology randomized controlled trial with a drug intervention (doxorubicin/trastuzumab) and reports a primary efficacy endpoint (cardiorespiratory fitness). However, it lacks the required time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or HR from Kaplan-Meier) and does not establish a definitive phase (III/IIIb or II/III).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nitroglycerin Plus Whole Intracranial Radiation Therapy for Brain Metastases in Patients With Non-Small Cell Lung Cancer: A Randomized, Open-Label, Phase 2 Clinical Trial. PMID 35157994 · Int J Radiat Oncol Biol Phys · 2023-Mar-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients. PMID 37099027 · Semin Hematol · 2023-Mar The record is a consensus statement summarizing and updating guidelines. While it references Phase III randomized trials, it does not present original formal results of such a trial. It is a review/guideline, not a primary report of a clinical trial with a time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Early-Phase Partial Mayo Score following Golimumab Treatment Is Associated with Endoscopic Improvement at 1 Year in Ulcerative Colitis: A post hoc Analysis of PURSUIT-J Randomized Controlled Trial. PMID 37064537 · Inflamm Intest Dis · 2023-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A randomised, controlled, feasibility trial of an online, self-guided breathlessness supportive intervention (SELF-BREATHE) for individuals with chronic breathlessness due to advanced disease. PMID 37057089 · ERJ Open Res · 2023-Mar The study is a randomized feasibility trial, not a definitive Phase III efficacy trial. It lacks a time-to-event efficacy endpoint and uses a non-drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial. PMID 37052965 · Lancet Oncol · 2023-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS. PMID 36987836 · Future Oncol · 2023-Mar The abstract describes the rationale and design of an ongoing randomized phase II/III trial, but does not report any results, including the required time-to-event efficacy endpoints. Therefore, it is excluded as a protocol without results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy. PMID 36948507 · J Immunother Cancer · 2023-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A complex communication skills training program for physicians providing advanced cancer care - content development and barriers and solutions for implementation. PMID 36919800 · J Commun Healthc · 2023-Mar The study is a randomized controlled trial in oncology, but the provided abstract describes an educational intervention (communication skills training) and its implementation barriers, not the results of a drug-containing Phase III/IIIb or Phase II/III trial with a primary time-to-event efficacy endpoint. Therefore, it does not meet the core eligibility criteria for inclusion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Fear of cancer recurrence therapy (FORT): A randomized controlled trial. PMID 36862474 · Health Psychol · 2023-Mar The study is an oncology randomized trial in humans with primary results, but it evaluates a psychological therapy (FORT) for fear of cancer recurrence, not a drug-containing intervention, and uses patient-reported outcome measures (FCRI scores) rather than a time-to-event efficacy endpoint like OS or PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial. PMID 36860268 · Hemasphere · 2023-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
[Radiation or Surgery for HPV-positive oropharyngeal cancer? The ORATOR2 Trial - Comparing apples and oranges]. PMID 36858059 · Laryngorhinootologie · 2023-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Ravulizumab for the treatment of myasthenia gravis. PMID 36852670 · Expert Opin Biol Ther · 2023-Mar 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Open vs robotic intracorporeal Padua ileal bladder: functional outcomes of a single-centre RCT. PMID 36847812 · World J Urol · 2023-Mar The report is an original, randomized, human oncology trial with a primary time-to-event endpoint, but it is not an explicit Phase III/IIIb or Phase II/III trial and does not explicitly include a drug-containing intervention (the comparison is surgical technique: open vs robotic cystectomy).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. PMID 36823302 · Nat Med · 2023-Mar The study is explicitly a phase 1 trial (per title, abstract, and publication type) with a pharmacodynamic primary endpoint (tumor 2-HG concentration). It lacks the required phase (Phase III/IIIb or definitive Phase II/III) and a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) to meet eligibility criteria.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial. PMID 36816343 · EClinicalMedicine · 2023-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer. PMID 36815433 · Future Oncol · 2023-Mar This is a plain language summary (lay summary) of a published Phase III trial, not the original formal-result report. The abstract does not explicitly report specific time-to-event efficacy endpoints (e.g., OS, PFS, DFS, HR, Kaplan-Meier curves) with numerical data, only general statements of benefit.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study. PMID 36762512 · ACR Open Rheumatol · 2023-Mar The study is a Phase 3 randomized trial of a drug (guselkumab) in humans, but the disease is psoriatic arthritis, not a human malignant neoplasm. Furthermore, the primary efficacy endpoints are categorical response rates (ACR20/50, MDA) and not time-to-event outcomes like OS, PFS, DFS, EFS, RFS, TTP, or analyses with Kaplan-Meier/HR.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development. PMID 36759721 · Br J Cancer · 2023-Mar 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L B
旧查询独有 eligibleexplicit_phase3_randomized confirmed 3 Figure · 5 Panel · risk visible
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. PMID 36758420 · Gynecol Oncol · 2023-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study. PMID 36753836 · Eur J Cancer · 2023-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial. PMID 36739879 · Lancet Oncol · 2023-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
μ-opioid receptor agonist facilitates circulating tumor cell formation in bladder cancer via the MOR/AKT/Slug pathway: a comprehensive study including randomized controlled trial. PMID 36739595 · Cancer Commun (Lond) · 2023-Mar The report is a mixed preclinical/clinical study investigating a mechanism (MOR agonist effect on CTC formation) in bladder cancer. While it includes a randomized controlled trial component, this is a small, early-phase, mechanistic/biomarker study, not a Phase III/IIIb or Phase II/III trial with a primary time-to-event efficacy endpoint. The primary outcome is CTC count, not survival or progression.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Paradigm shift: should preoperative 3D reconstruction models become mandatory before hepatectomy for hepatocellular carcinoma (HCC)? Results of a multicenter prospective trial. PMID 36710089 · HPB (Oxford) · 2023-Mar The study is a non-randomized prospective trial evaluating a surgical/imaging technique, with no drug intervention and no time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A prognostic cuproptosis-related lncRNA predictive signature for bladder cancer patients. PMID 36709471 · Hum Cell · 2023-Mar The study is a bioinformatic/prognostic model analysis using public data (TCGA) and in vitro experiments, not an original report of a randomized controlled trial. While it mentions a 'Randomized Controlled Trial' publication type and discusses survival outcomes, it does not present results from a specific drug-containing intervention trial. No Phase III or definitive trial phase is established, and no trial-level Kaplan-Meier or HR data for a drug intervention are reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[Can computer alerts in general practitioners' software upgrade cancer screening participation? A monocentric randomized study in France]. PMID 36707256 · Bull Cancer · 2023-Mar Study is a randomized controlled trial in human oncology (colorectal cancer screening) with original results, but it is not a Phase III/IIIb or Phase II/III trial, has no drug-containing intervention (it evaluates a computer alert system), and does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial. PMID 36706645 · Gynecol Oncol · 2023-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Nonskeletal and skeletal effects of high doses versus low doses of vitamin D3 in renal transplant recipients: Results of the VITALE (VITamin D supplementation in renAL transplant recipients) study, a randomized clinical trial. PMID 36695682 · Am J Transplant · 2023-Mar The study is a randomized trial reporting primary results with a time-to-event endpoint (hazard ratio for composite endpoint), but it is not an oncology-focused study. The primary endpoint is a composite of multiple non-cancer complications (diabetes, cardiovascular events, cancer, death) in renal transplant recipients, not a dedicated malignancy time-to-event endpoint like OS, PFS, DFS, etc. The intervention is cholecalciferol (vitamin D3), a dietary supplement, not a chemotherapeutic or targeted drug. Cancer is only one component of the composite endpoint, and the study does not report separate cancer-specific time-to-event outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer and skeletal metastases. PMID 36682096 · Eur J Cancer · 2023-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trial. PMID 36657324 · Eur J Cancer · 2023-Mar The record meets most eligibility criteria (oncology, human, randomized, time-to-event endpoint, drug intervention, original result), but the trial phase (Phase III/IIIb or Phase II/III) is not explicitly established in the provided metadata. Eligibility requires explicit confirmation of the phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial. PMID 36640794 · Lancet Gastroenterol Hepatol · 2023-Mar The study is a randomized controlled trial in Crohn's disease, not a malignant neoplasm. Therefore, it is ineligible for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Internet-delivered cognitive behavioural therapy for depression and anxiety in breast cancer survivors: Results from a randomised controlled trial. PMID 36635249 · Psychooncology · 2023-Mar The record is excluded because it does not meet the key eligibility criteria: it reports on a non-drug intervention (iCBT) and lacks a time-to-event primary/key secondary efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The study is an original randomized trial in human oncology, but it is not a drug-based Phase III/IIIb or Phase II/III trial with a time-to-event endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01). PMID 36608383 · Gynecol Oncol · 2023-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients. PMID 36602669 · Breast Cancer · 2023-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Clinical Trials of Prostate-Specific Membrane Antigen Radiopharmaceutical Therapy. PMID 36599704 · J Nucl Med Technol · 2023-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma. PMID 36595123 · Int J Clin Oncol · 2023-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Association between radiotherapy protocol variations and outcome in the CONVERT trial. PMID 36578530 · Clin Transl Radiat Oncol · 2023-Mar The report is a secondary analysis of radiotherapy quality assurance data from the Phase III CONVERT trial. While it involves a randomized trial and reports time-to-event efficacy endpoints (PFS, OS), it does not involve a drug-containing intervention; the analysis focuses solely on radiotherapy protocol variations and their association with outcomes, without evaluating a drug or systemic therapy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials. PMID 36541117 · Br J Haematol · 2023-Mar The record describes a joint analysis of relapse patterns and timing from two randomized trials (EORTC H10, NCRI RAPID). While it includes drug interventions (ABVD chemotherapy), the analysis focuses on descriptive relapse patterns (e.g., percentage relapsing within 2 years) and uses adjusted Cox models with time-varying effects to assess the impact of radiotherapy on risk of early relapse. The primary endpoints reported are relapse patterns and timing, not a standard time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, or TTP presented with Kaplan-Meier curves or Hazard Ratios. The phase of the underlying trials is not explicitly stated in the provided metadata. Therefore, it does not meet the strict requirement for a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -